FDA
-
-
-
-
-
-
-
AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-1
-
-
-
-
-
-
-
UPDATE - FMW Media, Inc.’s “New to The Street” TV Announces 6 Interviews Being Broadcast on NEWSMAX TV, Sunday, June 06, 2021, Hour Slot 10-11 AM ET
-
-
-
-
-
-
-
AzurRx BioPharma (AZRX) Initiates Phase 2 Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
-
-
-
-
-
-
-
AzurRx BioPharma (AZRX) CEO Issues Letter to Shareholders
-
-
-
-
-
-
-
AzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis Patients
-
-
-
-
-
-
-
AzurRx BioPharma Issues Letter to Shareholders
-
-
-
-
-
-
-
AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial
-
251,776 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All